In this article, published in Genetic Engineering and Biotechnology News, Matthew Majewski discusses three alternative reimbursement models to address the pricing challenges payers and manufacturers face to provide patient access to high-cost curative therapies.
To read the full article, click here.
The year in review: Updates and trends
In 2022, we witnessed intense activity in matters related to supply chain issues, the energy transition, oil & gas, post-M&A disputes, licensing issues,...